XML 52 R38.htm IDEA: XBRL DOCUMENT
v3.20.2

Acquisitions - Additional Information (Details) | 1 Months Ended | 9 Months Ended |  |  |  |
--- | --- | --- | --- | --- | --- | ---
Oct. 31, 2020 USD ($) | Jun. 30, 2020 USD ($) | May 31, 2020 Milestone | Sep. 30, 2020 USD ($) Milestone $ / shares | Dec. 31, 2019 USD ($) | Jan. 31, 2018 USD ($) | Aug. 31, 2017 USD ($) | Sep. 30, 2016 USD ($)
TomegaVax | TomegaVax Letter Agreement |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Milestone payments aggregate amount payable, maximum |  |  |  |  |  |  |  | $ 30,000,000.0
Minimum common stock conversion price for milestone payments consideration | $ / shares |  |  |  | $ 45 |  |  |  |
Milestone payments related terms |  |  |  | the Company will be required to pay to the former stockholders of TomegaVax milestone payments of up to an aggregate of $30.0 million if the per-share price of the Company’s publicly traded common stock, or implied price per share of the Company’s Series A-1 convertible preferred stock (or common stock upon conversion) upon a certain asset sale, merger or stock sale, is at least $45 (as adjusted in the case of any stock dividend, stock split or other similar recapitalization), with the amount of such payments determined by the share price and the stage of the Company’s clinical development at the time of the relevant event triggering the payment. |  |  |  |
Estimated fair value of embedded derivative |  |  |  | $ 9,500,000 |  |  |  |
Humabs |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Specified clinical development milestones payment |  | $ 10,000,000.0 |  |  |  |  |  |
Contingent consideration recognized |  |  |  | 42,500,000 | $ 14,900,000 |  |  |
Humabs | HBV Product |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Additional consideration payable upon achievement of specified milestone events |  |  |  |  |  |  | $ 135,000,000.0 |
Number of specified clinical milestones achieved | Milestone |  |  | 1 |  |  |  |  |
Specified clinical development milestones payment |  | $ 10,000,000.0 |  |  |  |  |  |
Contingent consideration recognized |  |  |  | 42,500,000 |  |  |  |
Humabs | SARS-CoV-2 Product |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Additional consideration payable upon achievement of specified milestone events |  |  |  |  |  |  | $ 105,000,000.0 |
Humabs | SARS-CoV-2 Product | Subsequent Event |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Specified clinical development milestones payment | $ 10,000,000.0 |  |  |  |  |  |  |
Agenovir |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Milestone payments aggregate amount payable, maximum |  |  |  |  |  | $ 180,000,000.0 |  |
Contingent consideration recognized |  |  |  | $ 0 |  |  |  |
Sales milestone payments for achievement of specified levels of annual net sales of each program maximum |  |  |  |  |  | 90,000,000.0 |  |
Number of milestones achieved | Milestone |  |  |  | 0 |  |  |  |
Agenovir | HPV Program |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Milestone payments aggregate amount payable, maximum |  |  |  |  |  | 45,000,000.0 |  |
Agenovir | HBV Product |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Milestone payments aggregate amount payable, maximum |  |  |  |  |  | $ 45,000,000.0 |  |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(3) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4B -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959 + Details
Name: | us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Business acquisition number of milestones achieved related to contingent consideration. + References No definition available. + Details
Name: | vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration
Namespace Prefix: | vir_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business acquisition number of specified clinical milestones achieved. + References No definition available. + Details
Name: | vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved
Namespace Prefix: | vir_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business combination sales milestone payments consideration. + References No definition available. + Details
Name: | vir_BusinessCombinationSalesMilestonePaymentsConsideration
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Business combinations additional consideration payable upon achievement of specified events. + References No definition available. + Details
Name: | vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Milestone payments related terms description. + References No definition available. + Details
Name: | vir_MilestonePaymentsRelatedTermsDescription
Namespace Prefix: | vir_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Minimum common stock conversion price for milestone payments consideration. + References No definition available. + Details
Name: | vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration
Namespace Prefix: | vir_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Specified clinical development milestones payment. + References No definition available. + Details
Name: | vir_SpecifiedClinicalDevelopmentMilestonesPayment
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_LetterAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_HepatitisBVirusProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_SARSCoV2ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=vir_AgenovirCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=vir_HumanPapillomavirusProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |